Cronos Group Inc (CRON)

Overview News Price History Option Chain Discussions Forecast

Cronos Group Inc stock is currently priced at $2.44, with a 24-hour trading volume of 3.86M. It has seen a -2.79% decreased in the last 24 hours and a +16.19% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.54 pivot point. If it approaches the $2.40 support level, significant changes may occur.

Cronos Group Inc Stock (CRON) Financials Data

Cronos Group Inc (CRON) Revenue 2023

CRON reported a revenue (TTM) of $87.89 million for the quarter ending December 31, 2023, a -1.33% decline year-over-year.

Cronos Group Inc (CRON) Net Income 2023

CRON net income (TTM) was -$73.96 million for the quarter ending December 31, 2023, a +56.17% increase year-over-year.

Cronos Group Inc (CRON) Cash Flow 2023

CRON recorded a free cash flow (TTM) of -$46.26 million for the quarter ending December 31, 2023, a +50.78% increase year-over-year.

Cronos Group Inc (CRON) Earnings per Share 2023

CRON earnings per share (TTM) was -$0.1843 for the quarter ending December 31, 2023, a +59.04% growth year-over-year.

Cronos Group Inc Stock (CRON) Latest News

Why Marijuana Stocks Got Burnt Today

The Motley Fool

NASDAQ-Listed Marijuana Stocks, Tilray, Canopy, Aurora Rally: What's Behind The Surge?

Benzinga

Why Canopy Growth, Cronos, and Aurora Cannabis Stocks Popped on Monday

The Motley Fool

Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session

Benzinga

Why Canadian Marijuana Stocks Popped Today

The Motley Fool

Why Marijuana Stocks Are Hopping Again on Tuesday

The Motley Fool

Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations “MMPR”. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.

Initiated	Bernstein: Mkt Perform	Nov-02-22
Upgrade	Canaccord Genuity: Hold → Buy	Jul-28-22
Upgrade	CIBC: Neutral → Sector Outperform	May-11-22
Upgrade	Barclays: Underweight → Equal Weight	Mar-22-22
Upgrade	Jefferies: Underperform → Hold	Jan-27-22
Resumed	BofA Securities: Underperform	Nov-18-21
Resumed	BofA Securities: Underperform	Apr-28-21
Downgrade	CIBC: Sector Outperform → Neutral	Feb-22-21
Upgrade	Raymond James: Mkt Perform → Outperform	Jun-24-20
Downgrade	Raymond James: Outperform → Mkt Perform	Apr-27-20
Downgrade	Piper Sandler: Overweight → Neutral	Apr-14-20
Downgrade	BofA/Merrill: Buy → Neutral	Apr-02-20
Downgrade	Canaccord Genuity: Hold → Sell	Mar-31-20
Upgrade	MKM Partners: Neutral → Buy	Mar-04-20
Downgrade	Stifel: Buy → Hold	Mar-03-20
Upgrade	Stifel: Hold → Buy	Oct-18-19
Initiated	MKM Partners: Neutral	Sep-20-19
Upgrade	BMO Capital Markets: Underperform → Market Perform	Sep-05-19
Initiated	Piper Jaffray: Overweight	Aug-13-19
Upgrade	Canaccord Genuity: Sell → Hold	Aug-09-19
Initiated	Consumer Edge Research: Equal Weight	Jun-28-19
Initiated	Stifel: Hold	Jun-06-19
Upgrade	BofA/Merrill: Underperform → Buy	Jun-05-19
Initiated	BofA/Merrill: Underperform	Apr-17-19
Downgrade	Canaccord Genuity: Hold → Sell	Mar-27-19
Initiated	Jefferies: Underperform	Feb-25-19
Initiated	CIBC: Sector Outperform	Jan-18-19